Oncology Phase 1 Deal Benchmarks — Europe (2026)
Median upfront of $32M with total deal values reaching $454M in Europe territory.
Median Upfront
$32M
Total Deal Value
$313M
Royalty Range
4%–9.4%
Territory Multiplier
0.25x
Understanding Oncology Deal Benchmarks at Phase 1
Phase 1 Oncology licensing deals in Europe territory command a median upfront payment of $32M, with values ranging from $15M at the low end to $49M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the oncology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $172M to $454M, with a median of $313M. Royalty rates for oncology assets at this stage typically fall between 4% and 9.4% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Europe territory applies a 0.25x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating europe rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $15M | $32M | $49M |
| Total Deal Value | $172M | $313M | $454M |
| Royalty Rate | 4% | — | 9.4% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2024 | Hansoh Pharmaceutical | Merck | $118M | $1.9B | licensing |
| 2023 | CSPC Pharmaceutical | Elevar Therapeutics | $60M | $700M | licensing |
| 2024 | Innovent Biologics | Sanofi | $300M | $2.3B | licensing |
| 2024 | Menarini Group | N/A (EU commercialization) | $0M | $800M | licensing |
| 2024 | Hengrui Medicine | Merck | $160M | $1.6B | licensing |
| 2024 | Kelun-Biotech | AbbVie | $200M | $1.4B | licensing |
| 2024 | Ipsen | Exelixis | $0M | $950M | licensing |
| 2023 | Epizyme | Ipsen | $247M | $247M | licensing |
See All Comparable Deals
View 8 comparable Oncology transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 1 Oncology deals in Europe territory?
How does Europe territory affect Oncology deal value?
What royalty rates are typical for Phase 1 Oncology licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$16M upfront
Oncology · Preclinical · Europe
$59M upfront
Oncology · Phase 2 · Europe
$154M upfront
Oncology · Phase 3 · Europe
$237M upfront
Oncology · Approved · Europe
$34M upfront
Neurology/CNS · Phase 1 · Europe
$41M upfront
Immunology · Phase 1 · Europe
$94M upfront
Metabolic/Obesity · Phase 1 · Europe
$128M upfront
Oncology · Phase 1 · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Oncology Phase 1 Deal Benchmarks — Europe (2026). Retrieved from https://solidus.ambrosiaventures.co/data/oncology-phase-1-deals-europe
<a href="https://solidus.ambrosiaventures.co/data/oncology-phase-1-deals-europe">Oncology Phase 1 Deal Benchmarks — Europe (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=oncology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.